NYSE: CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$8.91B
52w High
$228.88
52w Low
$144.26
P/E
-49.04
Volume
1.17M
Outstanding Shares
48.17M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 27.33% over the last year. Revenue grew 0.11% over the trailing twelve months. Operating margin moved from 4.38% to 11.77%. Free cash flow declined 30.53% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 11.77%. A decisive move in revenue — currently up 0.11% — would be the clearest signal to resolve the ambiguity.
Company profile
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
27
Buy
10
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 5, 2026
Q3 FY26 · EPS est $2.72 · Revenue est $977.95M
View